Positive Phase II Data Further Highlights Clinical Proof of Concept for Evobrutinib, First Oral Bruton's Tyrosine Kinase, BTK, Inhibito

 
1
 
16- 5 -2019
Evobrutinib is the first oral, highly selective Bruton's tyrosine kinase, BTK, inhibitor to show clinical proof of concept in RMS. Previously reported data showed that the study had met its primary endpoint over 24-weeks of treatment, where the ...
Gli articoli sono stati selezionati e posizionati in questa pagina in modo automatico. L'ora o la data visualizzate si riferiscono al momento in cui l'articolo è stato aggiunto o aggiornato in Libero 24x7